115 related articles for article (PubMed ID: 37143385)
1. Rapid high performance liquid chromatography method for erlotinib quantification in vitro: Application to study the effect of resveratrol on metabolism and cellular uptake of erlotinib.
Zayed A; Al Hroot J; Mayyas A; Al-Husein B
Fundam Clin Pharmacol; 2023 Oct; 37(5):983-993. PubMed ID: 37143385
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous quantification of atorvastatin, erlotinib and OSI-420 in rat serum and liver microsomes using a novel liquid chromatography-mass spectrometry method.
Rysz MA; Kinzi J; Schäfer AM; In-Albon K; Zürcher S; Schmidlin S; Seibert I; Schwardt O; Ricklin D; Meyer Zu Schwabedissen HE
J Pharm Biomed Anal; 2023 Nov; 236():115716. PubMed ID: 37722165
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients.
Svedberg A; Vikingsson S; Vikström A; Hornstra N; Kentson M; Branden E; Koyi H; Bergman B; Gréen H
Br J Clin Pharmacol; 2019 Aug; 85(8):1704-1709. PubMed ID: 30945322
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA.
Nie P; Hu W; Zhang T; Yang Y; Hou B; Zou Z
Cell Physiol Biochem; 2015; 35(6):2255-71. PubMed ID: 25895606
[TBL] [Abstract][Full Text] [Related]
5. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
6. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats.
Qin X; Lu J; Wang P; Xu P; Liu M; Wang X
Biochem Pharmacol; 2017 Nov; 143():129-139. PubMed ID: 28716728
[TBL] [Abstract][Full Text] [Related]
8. Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats.
Li J; Liu Y; Zhang J; Yu X; Wang X; Zhao L
Drug Des Devel Ther; 2016; 10():3699-3706. PubMed ID: 27895462
[TBL] [Abstract][Full Text] [Related]
9. Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib.
Dong PP; Fang ZZ; Zhang YY; Ge GB; Mao YX; Zhu LL; Qu YQ; Li W; Wang LM; Liu CX; Yang L
Acta Pharmacol Sin; 2011 Mar; 32(3):399-407. PubMed ID: 21372830
[TBL] [Abstract][Full Text] [Related]
10. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Li J; Zhao M; He P; Hidalgo M; Baker SD
Clin Cancer Res; 2007 Jun; 13(12):3731-7. PubMed ID: 17575239
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients.
Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B
J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880
[TBL] [Abstract][Full Text] [Related]
12. Humanization of
Rysz M; Schäfer AM; Paloumpis N; Kinzi J; Brecht K; Seibert I; Schmidlin S; In-Albon K; Ricklin D; Meyer Zu Schwabedissen HE
J Pharmacol Exp Ther; 2024 Mar; 389(1):87-95. PubMed ID: 38448247
[TBL] [Abstract][Full Text] [Related]
13. A High-Performance Liquid Chromatography with Photodiode Array Detection Method for Simultaneous Determination of Three Compounds Isolated from
Keem MJ; Seo SW; Kim T; Jo BG; Kim SN; Yoon IS; Yang MH
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764844
[TBL] [Abstract][Full Text] [Related]
14. In vitro determination of the CYP 3A4 activity in rat hepatic microsomes by liquid-phase extraction and HPLC-photodiode array detection.
Baati T; Horcajada P; Gref R; Couvreur P; Serre C
J Pharmacol Toxicol Methods; 2012 Jul; 66(1):29-34. PubMed ID: 22643301
[TBL] [Abstract][Full Text] [Related]
15. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Pathway of Icotinib In Vitro: The Differential Roles of CYP3A4, CYP3A5, and CYP1A2 on Potential Pharmacokinetic Drug-Drug Interaction.
Zhang T; Zhang K; Ma L; Li Z; Wang J; Zhang Y; Lu C; Zhu M; Zhuang X
J Pharm Sci; 2018 Apr; 107(4):979-983. PubMed ID: 29247736
[TBL] [Abstract][Full Text] [Related]
17. The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro.
Zhan YY; Liang BQ; Li XY; Gu EM; Dai DP; Cai JP; Hu GX
Xenobiotica; 2016; 46(5):439-44. PubMed ID: 26391142
[TBL] [Abstract][Full Text] [Related]
18. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
[TBL] [Abstract][Full Text] [Related]
19. In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry.
Santamaria R; Pailleux F; Beaudry F
Biomed Chromatogr; 2014 Dec; 28(12):1660-9. PubMed ID: 24729431
[TBL] [Abstract][Full Text] [Related]
20. Determination of metabolic profile of anti-malarial trioxane CDRI 99/411 in rat liver microsomes using HPLC.
Mishra S; Manickavasagam L; Jain GK
Biomed Chromatogr; 2012 Jan; 26(1):115-22. PubMed ID: 21503937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
